Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NNVC to Nasdaq or Amex?
And stay well above $3 per share for the foreseeable future. Whether you believe All Allan or not, you know this stock has been accumulating, you know it is under valued, and you know that all that is needed is one objective event to put all drug pipelines in play. There are many objective events possible in the very near future. When you know it, you just know it.
That would suggest a Big Pharma deal.
I got the auto thank you response.
I sent this message to the Bill and Melinda Gates Foundation.
We'll see said the Zen Master
Yesterday was the last day to sell within 30 days of the new calendar year. Now is the time to pour on the news. Read’m and weep.
This may be the why:
China expert warns of pandemic flu mutation
http://www.reuters.com/article/healthNews/idUSTRE5AO16220091125
Except the average daily volume has doubled over the last 6 months. MMs can make room for "special" clients to get in while there is time and they both get rich.
Dr Anthony Fauci
Here is another who's carreer should resonate with Nanoviricides endeavors.
Could you imagine him doing a story on Nanoviricides?
http://video.foxnews.com/11638196/dr-anthony-fauci
My take: In my line of work, I frequently give briefings to a wide variety folks that can range between experts or novices but important decision makers none the less. I have found that an effective way to get from point A to point B in a timely manner, and not loose the audience, is to review (summerize) the facts or the data or the history of the issue, before I proceed with the latest findings or dive in to deeper technical discussions. Everyone is now level set on the logic that follows. It’s just good briefing practice, especially when there is time pressure to make your points and to help move the decision process along.
Clearly, the word “cure” is really a statistical assessment. You are correct, the word “cure” can be abused and its users are subject to many spears and arrows. Just by being correct, (as you usually are Dr FG – thank you), you make my point.
If you were dying of H1N1 complications or HIV/AIDS would you want the standard drugs with low percentages of success or, would you want the drug that is 1,000 to 2,500 times more effective at killing what ails you?
By the way, SuperSquirrel earned his/her stripes with the Dr Rife story. That is pulling one out of the annals. My take away from that line of reasoning is that it makes me appreciate the careful studies that are being done by very reputable entities like TheVac and SRI on NNVC products. Results can be duplicated and validated in this case.
How did we get here?
1) How is it that thousands around the world will die of HIV/AIDS each year, and millions more infected and a functional cure exits?
2) How is it that a real cure for all kinds of Flu exists when likely a billion people will catch it, swine or otherwise, and thousands will die from it unnecessarily each year?
3) How is it that a cure for genital herpes exists for the 1 in 4 who have it and there is no apparent market interest?
4) How is it that a cure for EKC is proven and no big pharma wants to reveal their name while testing it?
5) How is it that a cure for rabies exists and no funding to develop the antidote is available?
6) How is it that a cure for dengue fever exists and no funding to develop the antidote is available?
7) How is it that a cure for hepatitis is right around the corner, and no one seems to care?
8) How is it that we are on the knee of the curve for the cure for many viral diseases, like penicillin was to bacteria, and the market is a sleep?
9) How have we as a culture, a country, and a people, lost the ability to make cures like these available to dying people right now?
I have seen in my 50 plus years of life that these kind of inequities do correct over time. It is just a matter of time. Everyone knows it.
MK, You are missing the big picture. NNVC has exclusive, perpetual licenses with TheraCour to “this technology” (from latest 10k). The answer to your question is emphatically, yes. Does NNVC have the rights to sell materials produced by TheraCour? Yes. Have they sold any of these materials? No. It is not a matter of what but when. Can NNVC get to a point of closing a deal with a big pharma, or government agency before capital funding runs dry will be the only real question until the first deal. Then, everything takes off. It is an all or nothing gamble. If not, then all this corporate structure is unnecessary. If yes, then TheraCour will get rich too (through subcontracts for production and equity in NNVC) if NNVC closes the deal. This corporate structure was created to protect the IP and raise capital through public offerings. Will NNVC stock holders get rich if TheraCour gets rich by this scenario? Of course. Could NNVC go toxic? Like any penny stock with no revenue, yes. Have they? No. I think this makes the logic for big pharmas either all in or all out. That is, either make a play for all the promising NNVC antivirals or none. All it takes is one event, like approval by the government for experimental use of FluCide, which they now have the power to do with a stroke of a pen, and we are in orbit.
You left off 4)MM manipulation. Its a penny stock. Remember!
This could have been Flucide.
http://www.foxnews.com/story/0,2933,569568,00.html
Great post. Romanus did not pass the smell test.
"I would urge anyone to disqualify any of the facts I presented" - Pablo Y. Romanus, M.D.
Well, someone should correct him. Facts are facts, and he made factual mistakes in that article regarding NNVC's technology. I don't really care if his feelings were hurt or what kind of guy Adam Feuerstein is. I don't see any correction to what Romanus said about NNVC in the previous article in this article.
It's called market maker (MM) manipulation. It's illegal. On the OTBB, the SEC punts and does not police this practice. MMs conspire to drive the price up or down depending on their own selfish interests. Typically it is driven down by shorts even by what is called "naked shorts", which is illegal, to drive the price down so MMs can make buckos on downward price sells and upward price spikes. MMs suck! Until the SEC grows some balls or this stock makes the NASDAQ, or the MMs get suprised by a Big Pharma deal, this practice will continue.
A public correction might be a blessing in disguise.
I wonder how much this "typo" cost NexBio?
UN report says pandemic may result in anarchy unless western world pays for antiviral drugs and vaccines
Swine flu 'could kill millions unless rich nations give £900m'
Rajeev Syal, The Observer, Sunday 20 September 2009
A woman wears a mask as preventive measure against swine flu, at Sassoon hospital in Pune, India, Aug 11, 2009. Photograph: Dhiraj Singh/AP
The swine flu pandemic could kill millions and cause anarchy in the world's poorest nations unless £900m can be raised from rich countries to pay for vaccines and antiviral medicines, says a UN report leaked to the Observer.
The disclosure will provoke concerns that health officials will not be able to stem the growth of the worldwide H1N1 pandemic in developing countries. If the virus takes hold in the poorest nations, millions could die and the economies of fragile countries could be destroyed.
Health ministers around the globe were sent the warning on Thursday in a report on the costs of averting a humanitarian disaster in the next few months. It comes as officials inside the World Health Organisation, the UN's public health body, said they feared they would not be able to raise half that amount because of the global downturn.
Gregory Hartl of WHO said the report required an urgent response from rich nations. "There needs to be recognition that the whole world is affected by this pandemic and the chain is only as strong as its weakest link. We have seen how H1N1 has taken hold in richer nations and in the southern hemisphere. We have been given fair warning and must act soon," he said.
The report was drawn up by UN officials over the last two months. It was commissioned in July after Ban ki-moon, the UN's secretary general, expressed concern that the H1NI virus could have a severe impact on the world's poorest countries.
It paints a disastrous picture for the world's most vulnerable people unless there is immediate action. "There is a window in which it will be possible to help poor countries get as ready as they can for H1N1 and that window is closing rapidly," it says.
"Countries where health services are overburdened by diseases, such as HIV/Aids, tuberculosis and malaria, will have great difficulty managing the surge of cases. And if the electricity and water sectors are not able to maintain services, this will have serious implications for the ability of the health sector to function.
"If suppliers of fuel, food, telecommunications, finance or transport services have not developed plans as to how they would continue to deliver their services, the consequences could be significantly intensified," it adds.
The 47-page report provides a detailed breakdown of the basic needs of 75 vulnerable countries with the weakest capacity to withstand an escalation of the virus. Six countries from Latin America, including Cuba and Bolivia, 21 countries from Asia and the Pacific such as North Korea and Bangladesh, and 40 countries from Africa such as Congo and Eritrea are included in the survey.
UN officials say in the report that £700m should be spent on antiviral drugs and vaccines to protect health care workers and other essential personnel as well as cover those suffering from severe illness. They have identified 85 countries that do not have the ability to access vaccines from any other source and intend to cover 5-10% of each population.
A further £147m should be put aside to organise vaccine campaigns, improve communications, monitor levels of illness and improve laboratory capacity in 61 countries, the report claims. The remainder should be used to pay for the WHO and other UN-related organisations to help in these countries as well as an emergency fund for additional antiviral medicines, it argues.
The UN's efforts were boosted last week when nine countries, including Britain and the US, pledged to give the equivalent of a 10% share of their swine flu vaccine supply to help fight the deadly virus's global spread. In Britain, Douglas Alexander, the development secretary, pledged to give £23m.
Some officials within WHO believe, however, that this will not be enough. One said that richer countries were reluctant to pay out all of the money that was needed. "The downturn means that governments countries are reluctant to give," he said.
Another said: "The money is a trickle, not a flood. It is going to be a struggle. If we are not careful, the virus could destroy a burgeoning economy or democracy."
The UN's request for the money comes as the virus begins to establish itself in some of the world's most vulnerable countries. On Wednesday, health officials told one website that the African continent had recorded 8,187 confirmed cases of swine flu and 41 deaths.
Swine flu was declared a pandemic in June and has since been identified in 180 countries. Pandemic experts believe that the western world, including Britain, is facing a second wave of the virus.
http://www.guardian.co.uk/world/2009/sep/20/swine-flu-costs-un-report
Chikungunya = cha-ching$ for NNVC
Based on our last PR, here is a chance to show the world how fast NNVC technology can meet the threat.
http://www.reuters.com/article/healthNews/idUSTRE58H60320090918?feedType=RSS&feedName=healthNews&rpc=22&sp=true
About Thomson Reuters
Mosquito-borne African virus a new threat to West
Fri Sep 18, 2009 6:53pm EDT
By David Morgan
WASHINGTON (Reuters) - The United States and Europe face a new health threat from a mosquito-borne disease far more unpleasant than the West Nile virus that swept into North America a decade ago, a U.S. expert said on Friday.
Chikungunya virus has spread beyond Africa since 2005, causing outbreaks and scores of fatalities in India and the French island of Reunion. It also has been detected in Italy, where it has begun to spread locally, as well as France.
"We're very worried," Dr. James Diaz of the Louisiana University Health Sciences Center told a meeting on airlines, airports and disease transmission sponsored by the independent U.S. National Research Council.
"Unlike West Nile virus, where nine out of 10 people are going to be totally asymptomatic, or may have a mild headache or a stiff neck, if you get Chikungunya you're going to be sick," he said.
"The disease can be fatal. It's a serious disease," Diaz added. "There is no vaccine."
Chikungunya infection causes fever, headache, fatigue, nausea, vomiting, muscle pain, rash and joint pain. Symptoms can last a few weeks, though some suffers have reported incapacitating joint pain or arthritis lasting months.
The disease was first discovered in Tanzania in 1952. Its name means "that which bends up" in the Makonde language spoken in northern Mozambique and southeastern Tanzania.
The virus could spread globally now because it can be carried by the Asian tiger mosquito, which is found in Asia, Africa, Europe, the Americas, Australia and New Zealand.
In the United States, the mosquito species tends to live in southern regions east of the Mississippi but has been found as far afield as western Texas, Minnesota and New Jersey.
Health officials are greatly concerned about the appearance of Chikungunya in the islands of the Indian Ocean -- Mauritius, Seychelles and Reunion -- which have beach resorts frequented by European tourists.
"It is hyper-endemic in the islands of the Indian Ocean," Diaz told the meeting.
"Travel by air will import the infected mosquitoes and humans," he added. "Chikungunya is coming."
Diaz warned of possible double-infections involving Chikungunya and dengue fever or malaria, which are also carried by the Asian tiger mosquito.
The spread of the disease could be greatest in so-called mega-cities such as Mumbai and Mexico City, which have large and impoverished populations, poor health controls and water systems that provide ready breeding grounds for mosquitoes, Diaz said.
West Nile, spread by a different mosquito species, first appeared in New York in 1999 and now can be found in most of North America.
(Editing by Maggie Fox and Paul Simao)
We will gap to $5 on the first PR with a big pharma deal. We will ramp to $20 in 2 – 3 weeks after that. When the masses get it, this stock will explode. This could be the stock of 21st century.
Send this to The Drudge Report,
especially if an english site (ie. no translation required) picks up on the story and it is confirmed.
Then, "Get Out of Town" ...
Now that's what I'm talking about.
Nice boat load of links to FluCide info.
Based on the excerpt below, from the last link dated May 26 2009, I would think that Thevac LLC will have some Flucide results on H1N1 to report out soon. The PR announcing the start of EKC studies at Thevac which also started the Herpes study, was published on June 15th 2009.
NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that it has signed a pre-clinical study agreement for the evaluation of FluCide, NanoViricides` universal anti-influenza drug candidate. The study will be
conducted by Thevac, LLC, a spin-off of the Louisiana State University (LSU), Baton Rouge, LA. It will be performed in collaboration with the Division of Biotechnology and Molecular Medicine at the LSU School of Veterinary Medicine,
which administers the LSU-Tulane Center for Experimental Infectious Disease Research (Director, K. G. Kousoulas, PhD)
Where did FluCide go?
All references to FluCide as highly effective against H1N1 are expired or missing from PR trails and NNVC website. It’s hard to find even a mention of it on this site.
I had to reply to myself just to put it back on the radar.
Did I miss something Doc?
WHO Warns of Severe Form of H1N1 Virus
(Perhaps NNVC FluCide HP might save lives in this case. )
Saturday, August 29, 2009
Doctors are reporting a severe form of H1N1 that goes straight to the lungs, causing severe illness in otherwise healthy young people and requiring expensive hospital treatment, the World Health Organization said Friday.
Some countries are reporting that as many as 15 percent of patients hospitalized with the new H1N1 pandemic virus need intensive care, further straining already overburdened healthcare systems, WHO said in an update on the pandemic.
"During the winter season in the southern hemisphere, several countries have viewed the need for intensive care as the greatest burden on health services," it said.
"Preparedness measures need to anticipate this increased demand on intensive care units, which could be overwhelmed by a sudden surge in the number of severe cases."
Earlier, WHO reported that H1N1 had reached epidemic levels in Japan, signaling an early start to what may be a long influenza season this year, and that it was also worsening in tropical regions.
"Perhaps most significantly, clinicians from around the world are reporting a very severe form of disease, also in young and otherwise healthy people, which is rarely seen during seasonal influenza infections," WHO said.” “ In these patients, the virus directly infects the lung, causing severe respiratory failure. Saving these lives depends on highly specialized and demanding care in intensive care units, usually with long and costly stays."
MINORITIES AT RISK
Minority groups and indigenous populations may also have a higher risk of being severely ill with H1N1.
"In some studies, the risk in these groups is four to five times higher than in the general population," WHO said.
"Although the reasons are not fully understood, possible explanations include lower standards of living and poor overall health status, including a high prevalence of conditions such as asthma, diabetes and hypertension."
WHO said it was advising countries in the Northern Hemisphere to prepare for a second wave of pandemic spread. "Countries with tropical climates, where the pandemic virus arrived later than elsewhere, also need to prepare for an increasing number of cases," it said.
RELATED STORIES
• Where Will You Get Your H1N1 Vaccine? Information Remains Unclear
Every year, seasonal flu infects between 5 percent and 20 percent of a given population and kills between 250,000 and 500,000 people globally. Because hardly anyone has immunity to the new H1N1 virus, experts believe it will infect far more people than usual, as much as a third of the population.
It also disproportionately affects younger people, unlike seasonal flu which mainly burdens the elderly, and thus may cause more severe illness and deaths among young adults and children than seasonal flu does.
"Data continue to show that certain medical conditions increase the risk of severe and fatal illness. These include respiratory disease, notably asthma, cardiovascular disease, diabetes and immunosuppression," WHO said.
"When anticipating the impact of the pandemic as more people become infected, health officials need to be aware that many of these predisposing conditions have become much more widespread in recent decades, thus increasing the pool of vulnerable people."
WHO estimates that more than 230 million people globally have asthma, and more than 220 million have diabetes. Obesity may also worsen the risk of severe infection, WHO said.
The good news — people infected with AIDS virus do not seem to be at special risk from H1N1, WHO said.
http://www.foxnews.com/story/0,2933,544262,00.html
Excellent post!
Thanks Doc (and Smooth).
I am an engineer by trade. Data is king! This is the best explanation for the “long haul” naysayer posters that I have seen. Naked shorting is just anther form of stealing. It is hard for the average investor to get this kind of data.
I hope we are headed out of this cesspool of penny stock vulchers soon. NASDAQ here we come.
Why do you post?
We all know why the longs post. They want to buy low and sell high. It is true, that the stock will not stay up until there is a big pharma deal. Everyone knows how long it takes to get something FDA approved. I do find the longs much more informative than the naysayers. The naysayers do have some points about promises made and promises gone by. But the recent headlines clearly show this is not a scam. It is real, and just a matter of time. Who knows when, but it feels soon.
But why go negative? Can the nay posters make money trying to scare this board of people out of their stock? Maybe a few. But is it worth that kind of time? I think not. It is a very short lived game, no pun intended. Yet the naysayers are here for the long haul. Why is that?
What would be the motive to bash a very promising drug development company for the long haul? Well here’s one:
A prospective big pharma client (who prefers nondisclosure) would like to make money on both ends. Once when the stock goes up on the PR disclosing the big pharma company and the deal and again when the drug hits the market. So, they hire folks to bash while they buy up the stock for a song. They are the same old names with the same old tired points. But they have deep pockets and can wait a long time. They can sell on news that is not a big pharma deal because they know the stock will go right back down in a few days and they can buy even more stock.
So, now we all know the equation. Sell on news that is not a big phama deal. Keep buying when its down.
Truth of the matter is, all this is liars poker anyway. So, I agree, “show me the money.”
Lots of ??? I think we got the draft PR. Probably means an upddate following close behind.
Good list to be on.
Penny stocks are not for the faint of heart.
In order to see these ratios you had to be in when it was scary. I think NNVC is due. It has much more than swine flu going for it.
NVAX : $4.64 52 week low: $0.52
BCRX : $9.31 52 week low: $0.85
SVA : $4.99 52 week low: $0.75
AVII : $2.41 52 week low: $0.45
NNVC : $0.76 52 week low: $0.39
Forget about vaccines, we will all either get it and survive or not. If you do the math, trying to stop the spread of the current mild strain of H1N1 swine flue is futile. It’s just too contagious.
If you keep up to date on “flu tracker” http://flutracker.rhizalabs.com/ , you can see the inevitable spread of swine flu into Africa and Asia is well underway. These lesser developed parts of the world are historically fertile breeding grounds for more lethal mutant forms of the virus, not to mention the potential of airborne HIV from Africa that has been posted as a concern by the WHO below.
The real battle line is containing these much more lethal scenarios. In these cases, antivirals such as, Flucide and HIVcide are the best weapon. I would hope someone in charge has figured that out.
http://www.alertnet.org/thenews/newsdesk/L2516414.htm
HIV patients at higher risk from flu, WHO says 02 May 2009 11:53:21 GMT
Source: Reuters
* HIV patients at high risk from flu, need antivirals most
* WHO fears complications if HIV and H1N1 viruses combine
(Adds background on HIV, seasonal influenza, antivirals)
By Laura MacInnis
GENEVA, May 2 (Reuters) - People with HIV are at high risk from the new flu strain that the World Health Organisation said is on the verge of a pandemic, the WHO said on Saturday.
The United Nations agency said people with immunodeficiency diseases -- including the AIDS virus -- will most likely be vulnerable to health complications from the H1N1 strain, as they are from regular seasonal flu, which kills between 250,000 and 500,000 people a year.
HIV and the new flu strain could also mix together in a dangerous way, as has occurred with HIV and tuberculosis, the WHO said in guidance for health workers on its website.
"Although there are inadequate data to predict the impact of a possible human influenza pandemic on HIV-affected populations, interactions between HIV/AIDS and A(H1N1) influenza could be significant," it said.
"HIV-infected persons should be considered as a high risk and a priority population for preventive and therapeutic strategies against influenza including emerging influenza A(H1N1) virus infection," it said.
The virus widely known as "swine flu" has been most severe in Mexico, where government authorities say it has killed more than 100 people, and caused more mild symptoms as it spread around the world to countries including the United States, Austria, Israel, New Zealand and South Korea. [L2430119]
Although the outbreak remains tiny in scale compared to other epidemics such as malaria, hepatitis, and meningitis, the WHO has raised its pandemic alert level to 5 out of 6 due to its rapid spread as well as the possibility that the flu could cause more devastation in poor and disease-prone communities.
Countries with high rates of HIV -- most of which are in Africa -- should work to ensure that vulnerable people get the drugs they need to fight off the flu infection, the WHO said.
Antiviral medicines such as Tamiflu and Relenza decrease the duration of virus excretion and the severity of illness when used for treatment of ill patients, and may also prevent illness when used for prophylaxis.
"Patients at higher risk for complications of influenza including those with HIV infection should be among those prioritised for antiviral treatment with oseltamivir or zanamivir which shortens illness duration and severity in seasonal influenza," the WHO guidance read.
It is best if people infected with the flu strain start to take the antivirals within 48 hours of the onset of symptoms, according to the WHO. There are no known problems with taking those drugs alongside the anti-retrovirals that HIV patients take to suppress their virus.
According to WHO estimates, there are 33 million people infected with immune-weakening HIV worldwide. (For the full WHO guidance for HIV patient care, see: http://www.who.int/hiv/mediacentre/influenza_hiv.pdf) (For a factbox on global diseases, click on [ID:nL2430119]) (For more Reuters swine flu coverage, please click here: http://www.reuters.com/news/globalcoverage/swineflu )
Now it's 1 in 2.
http://www.independent.co.uk/life-style/health-and-families/health-news/swine-flu-could-infect-up-to-half-the-population-1711552.html
Swine flu 'could infect up to half the population'
Health authorities told to set up testing and drug distribution centres in case of autumn outbreak
By Jonathan Owen
Sunday, 21 June 2009
Share
Close
Diggdel.icio.usFacebookRedditGoogleStumble UponFarkNewsvineYahooBuzzBeboMixxIndependent MindsPrintEmailText Size
NormalLargeExtra Large
afp
A medical researcher working to produce a DNA test for swine flu, which is spreading more quickly in the UK
enlarge
Primary care trusts are to set up anti-viral drug distribution centres and swine flu testing clinics amid fears that the infection could spread out of control.
The Chief Medical Officer, Sir Liam Donaldson, wrote to health authorities last week urging hospitals to test all patients who show signs of flu-like symptoms. He wrote: "Transmission from person to person in this country is increasingly common. There is evidence that sporadic cases are arising with no apparent link either to cases elsewhere in the UK or to travel abroad."
The letter followed an earlier warning from Sir Liam that millions of Britons could fall victim to swine flu in the coming months. Government officials admitted last night that illness rates from the virus could reach 50 per cent.
Related articles
•More Health Articles
Primary care trusts are now being briefed to expect that the pandemic could affect as much as 40 per cent of the workforce before the end of the year, with many worried that there could be a surge of cases in the autumn, according to health industry sources.
The Department of Health sought to reassure the public last night. A spokesman said: "Previous pandemics have seen total illness levels of 25-35 per cent. So our plans are as robust as possible, we have based them on illness rates of 50 per cent, though we do not anticipate it being this high in the current pandemic. Based on this figure, the workforce could be reduced by 15-20 per cent at the pandemic's peak. In the unlikely event that every school closed, this could rise to 35 per cent." He said it was impossible to predict when the pandemic would peak, but added: "As part of ongoing planning, the NHS is being asked to ensure that antiviral collection points could, if needed, be put into action in a week."
Keen to avoid panic, the Government is careful to present official statistics showing "laboratory-confirmed" cases, which currently stand at 2,244. Yet the true scale of infections is far higher than headline figures suggest. The total number of cases either confirmed by laboratory tests or "clinically presumed" currently stands at 3,725.
Almost 400 cases of swine flu in Britain have occurred as a result of in-country transmission, according to latest figures from the European Centre for Disease Control. The virus is continuing to gain ground, with a number of people falling ill without having been abroad or in contact with previously confirmed cases – a signal that transmission is "growing in some areas of the country", according to the Health Protection Agency. The HPA said: "We would need to have a significant number of people where you really don't know how they have got it for it to be classified as sustained community transmission. We are getting closer to that, but are not there yet."
This comes a week after Jacqui Fleming, 38, of Glasgow, became the first person to die from swine flu outside North America. Since then, health officials in Birmingham have said they can no longer contain the spread of the virus, and in Glasgow, a series of swine flu testing clinics have been set up.
Meanwhile, calls to NHS hotlines have almost doubled in the past week. Latest figures from NHS Direct reveal that 2,356 calls about swine flu were made on Thursday 18 June, up from 1,280 a week earlier.
Under a new scheme that began in June, hundreds of people calling NHS Direct about swine flu have been sent swab kits to return for testing.
Economic toll: Pandemic to cost Britain £42bn
£42bn losses are predicted to hit Britain as a result of a three per cent fall in gross domestic product (GDP) due to the swine flu pandemic, according to a new report from the Oxford Economics think tank, due to be released tomorrow. Researchers claim that swine flu could threaten already fragile businesses and put further strains on financial markets in what could become a "vicious cycle that postpones the recovery".
Deflation is a "significant risk" as a result of the pandemic's impact on the economy – putting back economic recovery by two years, says the report. The predictions are based on a 30 per cent infection rate, should a pandemic begin in October and last for six months.
A $2.5 trillion cut in global GDP is a possibility – with a flu outbreak in the autumn hitting the world economy just as it starts to recover from the credit crunch.
Novartis wouldn't have a conflict of interest in NNVC would they?
http://www.foxnews.com/story/0,2933,525937,00.html
Novartis Pharmaceuticals Corporation
5632 Sleepy Hollow Drive
Baton Rouge, LA 70817
225-752-8587 Voice
Pharmaceuticals
Roche Laboratories Inc Pharmaceutical
3850 N. Causeway Blvd
Metairie, LA 70002
504-828-3343 Voice
Pharmaceutical Preparation
Glaxo Wellcome Inc (GlaxoSmithKline)
38110 Seven Oaks Avenue
Prairieville, LA 70706
225-673-1750 Voice
Pharmaceutical Preparation
So,what is the TRL level (Technical Readiness Level) for Flucide HP?
Here's another one.
They (Replikins)claim to have a synthethic vaccine. If you listen closely its really an anti-viral. Sneaky marketing.
It appears that Replikins is not a publicly traded company. I am guessing that is why they get on the news and Nanoviricides does not, even though Nanoviricides is much further along in the testing phases.
http://www.replikins.com/index.html
Another flu strain in the mix (Type B).
http://www.alertnet.org/thenews/newsdesk/N06391128.htm
Second strain of flu may complicate picture-study 06 May 2009 15:02:09 GMT
Source: Reuters
* Mutations seen in seasonal flu strain
* May have caused Canadian late-season outbreak
* May complicate picture in Mexico
By Maggie Fox, Health and Science Editor
WASHINGTON, May 6 (Reuters) - A second strain of influenza, one of the seasonal strains, may have mutated and may be complicating the picture in Mexico, Canadian researchers reported on Wednesday.
They have found a strain of the H3N2 virus that appears to have made a shift and could have complicated the flu picture in Mexico, epicenter of an outbreak of a new strain of the H1N1 swine flu virus.
One was seen in a traveler returning from Mexico, the team at the British Columbia Centre for Disease Control reported to Pro-MED, an online forum for infectious disease experts. And it may have been involved in an unusually late outbreak of flu in long-term care facilities this year.
The new H1N1 virus has killed at least 42 people in Mexico and two in the United States, has spread globally and brought the world to the brink of a pandemic. It appears to act like seasonal flu but doctors have been confused because it has also killed some young and apparently healthy adults -- not the usual pattern for influenza, which picks off the elderly, chronically ill and very young.
Danuta Skowronski and colleagues said they routinely sequence the hemagglutinin gene from a sample of influenza viruses submitted each season by community doctors, hospitals and care facilities across the province of British Columbia, Canada. Hemagglutinin gives a flu virus the "H" in its name, as in H1N1 or H3N2, and is found on the surface of the virus.
Vaccines target hemagglutinin and when it changes, the vaccine must be changed, too. This year the vaccine targets strains of H3N2 influenza, an H1N1 strain different from the new swine flu strain, and an influenza B strain.
"Until mid-February 2009, amino acid sequences of the hemagglutinin gene of H3 viruses in British Columbia were virtually identical to the vaccine strain," Skowronski wrote.
"In early March 2009, however, we detected additional differences from the vaccine strain among British Columbia viruses collected from facility outbreak settings." They only found these changes in flu samples taken from patients in care facilities.
When news broke of the new H1N1 strain, they ran more tests.
"We have sequenced the hemagglutinin gene of one of the H3 viruses from an ill traveler returning from Mexico and find it shares the same ... changes," they wrote.
"In British Columbia, these H3 mutations arose sometime in early March 2009 and we observe at least one returning traveler to have likely acquired illness due to this virus in Mexico," they wrote.
"We thus also wonder to what extent the profile of influenza-like illness initially reported from mid-March in Mexico may in part be attributed to this H3N2 variant in addition to emergence of the novel A/H1N1 virus."
(Reporting by Maggie Fox, Editing by Sandra Maler)